Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | HTR6 | P50406 | 3/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.71 |
| ▸ | HTR2C | P28335 | 3/20 | 0.71 |
| ▸ | HTR1D | P28221 | 2/20 | 0.71 |
| ▸ | HTR1B | P28222 | 2/20 | 0.71 |
| ▸ | HTR7 | P34969 | 2/20 | 0.71 |
| ▸ | MPO | P05164 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | CTSK | P43235 | 1/20 | 0.71 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.71 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | AHR | P35869 | 1/20 | 0.69 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29484985 | 0.98 | HTR2A (0.69) | HTR2ACYP3A4HTR6CYP2D6HTR2C | |
| Hydrochloric Acid SCHEMBL5207471 | 0.98 | PMP22 (0.72) | HTR2ACYP3A4HTR6CYP2D6HTR2C | |
| Hydrochloric Acid SCHEMBL21546062 | 0.98 | PMP22 (0.72) | HTR2ACYP3A4HTR6CYP2D6HTR2C | |
| Oxalic Acid SCHEMBL4487013 | 0.89 | KMT2A (0.66) | HTR2ACYP3A4HTR6CYP2D6HTR2C | |
| Tryptamine SCHEMBL8714244 | 0.83 | HTR2A (1.00) | HTR2ACYP3A4HTR6CYP2D6HTR2C | |
| Tryptamine SCHEMBL26725 | 0.83 | HTR2A (1.00) | HTR2ACYP3A4HTR6CYP2D6HTR2C | |
| Tryptamine SCHEMBL29373222 | 0.83 | HTR2A (1.00) | HTR2ACYP3A4HTR6CYP2D6HTR2C | |
| Arundine SCHEMBL325162 | 0.82 | MEN1 (1.00) | HTR2ACYP3A4HTR6CYP2D6HTR2C | |
| SCHEMBL4985934 | 0.82 | HTR2A (0.77) | HTR2ACYP3A4HTR6CYP2D6HTR2C | |
| Tryptamine SCHEMBL274183 | 0.82 | PMP22 (1.00) | HTR2ACYP3A4HTR6CYP2D6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 474 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118908874-A | PAD4 inhibitor, preparation method thereof and application thereof in preparation of anti-pulmonary fibrosis drugs | 首都医科大学 | 2024-11-08 | — | — | CN | claimed |
| CN-118754840-A | Alpha, beta-unsaturated amide or hydrazide compound containing carbonyl structure, and preparation method and application thereof | 贵州大学 | 2024-10-11 | — | — | CN | claimed |
| US-20240092773-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2024-03-21 | — | — | US | claimed |
| CN-111153848-B | Method for synthesizing 3-aminomethylindole compound through non-catalytic Mannich reaction | 成都睿智化学研究有限公司 | 2023-07-28 | — | — | CN | claimed |
| CN-116133442-A | Perovskite solar cell based on organic molecule modified lithium salt doped hole transport layer | 陕西师范大学 | 2023-05-16 | — | — | CN | claimed |
| CN-114213395-B | Pyrimidone acyl piperazine compound and preparation method and application thereof | 山东大学 | 2022-10-25 | — | — | CN | claimed |
| CN-114213395-A | Pyrimidone acyl piperazine compound and preparation method and application thereof | 山东大学 | 2022-03-22 | — | — | CN | claimed |
| WO-2021130257-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | claimed |
| CN-111153848-A | Method for synthesizing 3-aminomethyl indole compound by non-catalytic Mannich reaction | 成都睿智化学研究有限公司 | 2020-05-15 | — | — | CN | claimed |
| EP-3510404-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | Pharmakea, Inc. (US) | 2019-07-17 | — | — | EP | claimed |
| WO-2011048390-A2 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-04-28 | — | — | WO | claimed |
| JP-4641942-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| US-20080194553-A1 | compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition,in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome | VEIJLEN N.V. (NL) | 2008-08-14 | — | — | US | claimed |
| CN-1938018-A | Use of compounds capable of increasing serum IGF-1 levels for the preparation of therapeutic compositions for the treatment of various disease states associated with decreased IGF-1 serum levels in humans and animals | VEIJLEN LTD (AN) | 2007-03-28 | — | — | CN | claimed |
| US-20070032489-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2007-02-08 | — | — | US | claimed |
| EP-1732896-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | Aventis Pharmaceuticals Inc. (US) | 2006-12-20 | — | — | EP | claimed |
| EP-1670444-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | Veijlen N.V. (AN) | 2006-06-21 | — | — | EP | claimed |
| WO-2005097750-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | claimed |
| WO-2005039546-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | VEIJLEN N.V. (AN) | 2005-05-06 | — | — | WO | claimed |
| EP-0037271-B1 | INDOLE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | TORAY INDUSTRIES, INC. (JP) | 1984-01-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092773-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | FCER2, FCGR2A, FCGR1A | HTR2A 1046/4885CYP3A4 698/4885HTR6 2425/4885 |
| US-20070032489-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP2, PARP3 | HTR2A 484/4885CYP3A4 987/4885HTR6 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.